olomoucine has been researched along with Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Ibrahim, DA; Ismail, NS | 1 |
| Chandrasekaran, B; Cherukupalli, S; Chinnam, S; Hampannavar, GA; Karpoormath, R; Kayamba, F; Reddy Aleti, R; Sayyad, N | 1 |
| Wandl, S; Wesierska-Gadek, J | 1 |
| Buquet-Fagot, C; Lallemand, F; Mester, J; Montagne, MN | 1 |
1 review(s) available for olomoucine and Neoplasms
| Article | Year |
|---|---|
An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.
Topics: Adenosine; Anti-Infective Agents; Antineoplastic Agents; Cytokinins; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Phosphoric Diester Hydrolases; Pyrazoles; Pyrimidines | 2018 |
4 other study(ies) available for olomoucine and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cyclin A; Cyclin D; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Drug Design; Enzyme Inhibitors; Humans; Models, Molecular; Neoplasms; Pyrimidines | 2011 |
Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?
Topics: Apoptosis; Caspase 3; Caspase 7; Cell Cycle; Cyclin-Dependent Kinase 2; DNA, Neoplasm; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Flow Cytometry; G1 Phase; G2 Phase; HeLa Cells; HL-60 Cells; Humans; Kinetin; Neoplasms; S Phase | 2009 |
Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines.
Topics: Cell Cycle; Cell Division; Cyclin-Dependent Kinases; Enzyme Inhibitors; Humans; Kinetin; Lovastatin; Neoplasms; Purines; Retinoblastoma Protein; Thymidine; Thymidine Kinase; Tritium; Tumor Cells, Cultured | 1997 |